Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion

Journal of Hematology and Oncology

Volumn 9, Issue 1, 2016, Pages

  Han, Lijuan ^a   Schubert, Claudia ^a   Köhler, Johanna ^a   Schemionek, Mirle ^a   Isfort, Susanne ^a   Brümmendorf, Tim H ^a   Koschmieder, Steffen ^a   Chatain, Nicolas ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Calreticulin; Degradation; del52; Frameshift mutants; Megakaryopoiesis; MPL; MPN; Myeloproliferative neoplasms; NF E2; Protein secretion

Indexed keywords

CALRETICULIN; FIBRINOGEN RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUTANT PROTEIN; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR NF E2; CALRETICULIN, HUMAN; GLYCOPROTEIN IIB; MPL PROTEIN, HUMAN; NFE2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; GOLGI COMPLEX; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MUTANT; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ANIMAL; CELL DEATH; CELL LINE; FRAMESHIFT MUTATION; GENETICS; METABOLISM; MOUSE; MYELOPROLIFERATIVE DISORDER; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; CALRETICULIN; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FRAMESHIFT MUTATION; GOLGI APPARATUS; HUMANS; MEGAKARYOCYTES; MICE; MUTANT PROTEINS; MYELOPROLIFERATIVE DISORDERS; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTEOLYSIS; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION;

EID: 84971254922     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-016-0275-0     Document Type: Article

References (43)

1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-405.
2. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-90.
3. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:162-73.
4. Beer P. The pathogenesis of essential thrombocythemia. Curr Opin Hematol. 2011;18:323-9.
5. Broséus J, Park J-H, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014;124:3964-6.
6. Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, et al. Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer J. 2015;5:e360.
7. Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, et al. Calreticulin (CALR) variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91:503-6.
8. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009;417:651-66.
9. Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor S-M, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24:665-83.
10. Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431-8.
11. Chachoua I, Pecquet C, El-Khoury M, Nivarthi H, Albu R-I, Marty C, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325-35.
12. Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127:1317-24.
13. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307-16.
14. Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 2016;6:368-81.
15. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood. 2011;117:2935-43.
16. Schneider C a, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-5.
17. Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. Am J Hematol. 2016;91:211-9.
18. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014;28:1811-8.
19. Jackers P, Szalai G, Moussa O, Watson DK. Ets-dependent regulation of target gene expression during megakaryopoiesis. J Biol Chem. 2004;279:52183-90.
20. Goldfarb AN. Transcriptional control of megakaryocyte development. Oncogene. 2007;26:6795-802.
21. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369:533-8.
22. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature. 1994;369:571-4.
23. Kostyak JC, Naik UP. Megakaryopoiesis: transcriptional insights into megakaryocyte maturation. Front Biosci. 2007;12:2050-62.
24. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005;102:18962-7.
25. Sevinsky JR, Whalen AM, Ahn NG. Extracellular signal-regulated kinase induces the megakaryocyte GPIIb/CD41 gene through MafB/Kreisler. Mol Cell Biol. 2004;24:4534-45.
26. Fock E, Yan F, Pan S, Chong BH. NF-E2-mediated enhancement of megakaryocytic differentiation and platelet production in vitro and in vivo. Exp Hematol. 2008;36:78-92.
27. Chen Y, Dai X, Haas AL, Wen R, Wang D. Proteasome-dependent down-regulation of activated Stat5A in the nucleus. Blood. 2006;108:566-74.
28. Wang D, Moriggl R, Stravopodis D, Carpino N, Marine JC, Teglund S, et al. A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. Embo J. 2000;19:392-9.
29. Choudhary C, Olsen JV, Brandts C, Cox J, Reddy PNG, Böhmer FD, et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell. 2009;36:326-39.
30. Chatain N, Perera RC, Rossetti G, Rossa J, Carloni P, Schemionek M, et al. Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine. Leukemia. 2015;29:2434-8.
31. Bosshart H, Straehl P, Berger B, Berger EG. Brefeldin A induces endoplasmic reticulum-associated O-glycosylation of galactosyltransferase. J Cell Physiol. 1991;147:149-56.
32. Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N. Calreticulin in the immune system: ins and outs. Trends Immunol. 2013;34:13-21.
33. Nivarthi H, Chen D, Cleary C, Kubesova B, Jäger R, Bogner E, et al. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. Leukemia. 2016; doi: 10.1038/leu.2016.32.
34. Jeong J-Y, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. J Hematol Oncol. 2015;8:37.
35. Kauskot A, Vandenbriele C, Louwette S, Gijsbers R, Tousseyn T, Freson K, et al. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood. 2013;121:5208-17.
36. Weng Z, Li D, Zhang L, Chen J, Ruan C, Chen G, et al. PTEN regulates collagen-induced platelet activation. Blood. 2010;116:2579-81.
37. Antón LC, Villasevil EM. Is there an alternative to the proteasome in cytosolic protein degradation? Biochem Soc Trans. 2008;36(Pt 5):839-42.
38. Klausner RD, Donaldson JG, Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992;116:1071-80.
39. Pelham HR. Multiple targets for brefeldin A. Cell. 1991;67:449-51.
40. Misumi Y, Misumi Y, Miki K, Takatsuki A, Tamura G, Ikehara Y. Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J Biol Chem. 1986;261:11398-403.
41. Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 2011;490:71-92.
42. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012;31:1062-79.
43. Booth C, Koch GL. Perturbation of cellular calcium induces secretion of luminal ER proteins. Cell. 1989;59:729-37.